154 related articles for article (PubMed ID: 28112746)
1. Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation.
Schetelig J; de Wreede LC; van Gelder M; Andersen NS; Moreno C; Vitek A; Karas M; Michallet M; Machaczka M; Gramatzki M; Beelen D; Finke J; Delgado J; Volin L; Passweg J; Dreger P; Henseler A; van Biezen A; Bornhäuser M; Schönland SO; Kröger N
Bone Marrow Transplant; 2017 Apr; 52(4):552-560. PubMed ID: 28112746
[TBL] [Abstract][Full Text] [Related]
2. Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT.
van Gelder M; Ziagkos D; de Wreede L; van Biezen A; Dreger P; Gramatzki M; Stelljes M; Andersen NS; Schaap N; Vitek A; Beelen D; Lindström V; Finke J; Passweg J; Eder M; Machaczka M; Delgado J; Krüger W; Raida L; Socié G; Jindra P; Afanasyev B; Wagner E; Chalandon Y; Henseler A; Schoenland S; Kröger N; Schetelig J;
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):667-675.e2. PubMed ID: 28694085
[TBL] [Abstract][Full Text] [Related]
3. Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT).
Schetelig J; de Wreede LC; Andersen NS; Moreno C; van Gelder M; Vitek A; Karas M; Michallet M; Machaczka M; Gramatzki M; Beelen D; Finke J; Delgado J; Volin L; Passweg J; Dreger P; Schaap N; Wagner E; Henseler A; van Biezen A; Bornhäuser M; Iacobelli S; Putter H; Schönland SO; Kröger N;
Br J Haematol; 2017 Aug; 178(4):521-533. PubMed ID: 28589551
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation.
van Gelder M; de Wreede LC; Bornhäuser M; Niederwieser D; Karas M; Anderson NS; Gramatzki M; Dreger P; Michallet M; Petersen E; Bunjes D; Potter M; Beelen D; Cornelissen JJ; Yakoub-Agha I; Russell NH; Finke J; Schoemans H; Vitek A; Urbano-Ispízua Á; Blaise D; Volin L; Chevallier P; Caballero D; Putter H; van Biezen A; Henseler A; Schönland S; Kröger N; Schetelig J
Bone Marrow Transplant; 2017 Mar; 52(3):372-380. PubMed ID: 27941763
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.
Schetelig J; van Biezen A; Brand R; Caballero D; Martino R; Itala M; García-Marco JA; Volin L; Schmitz N; Schwerdtfeger R; Ganser A; Onida F; Mohr B; Stilgenbauer S; Bornhäuser M; de Witte T; Dreger P
J Clin Oncol; 2008 Nov; 26(31):5094-100. PubMed ID: 18711173
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
Caballero D; García-Marco JA; Martino R; Mateos V; Ribera JM; Sarrá J; León A; Sanz G; de la Serna J; Cabrera R; González M; Sierra J; San Miguel J
Clin Cancer Res; 2005 Nov; 11(21):7757-63. PubMed ID: 16278397
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors to predict outcome of reduced intensity allogeneic haematopoietic cell transplantation for chronic lymphocytic leukemia.
Jindra P; Raida L; Lysak D; Karas M; Papajik T; Jungova A; Mohammadová L; Houdova L
Neoplasma; 2016; 63(4):595-600. PubMed ID: 27268923
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse.
Hahn M; Böttcher S; Dietrich S; Hegenbart U; Rieger M; Stadtherr P; Bondong A; Schulz R; Ritgen M; Schmitt T; Tran TH; Görner M; Herth I; Luft T; Schönland S; Witzens-Harig M; Zenz T; Kneba M; Ho AD; Dreger P
Bone Marrow Transplant; 2015 Oct; 50(10):1279-85. PubMed ID: 26146810
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].
Wang CY; Ren HY; Qiu ZX; Wang Y; Cen XN; Wang LH; Wang MJ; Xu WL; Wang WS; Li Y; Dong YJ; Ou JP; Liang ZY; Liu W; Wang Q
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):659-63. PubMed ID: 23978015
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Advanced Patient Age on Mortality after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: A Retrospective Study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party.
Kyriakou C; Boumendil A; Finel H; Nn Norbert Schmitz ; Andersen NS; Blaise D; Chevallier P; Browne P; Malladi R; Niederwieser D; Pagliuca A; Kroschinsky F; Montoto S; Dreger P;
Biol Blood Marrow Transplant; 2019 Jan; 25(1):86-93. PubMed ID: 30219698
[TBL] [Abstract][Full Text] [Related]
11. Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy.
Nakaya A; Mori T; Tanaka M; Tomita N; Nakaseko C; Yano S; Fujisawa S; Sakamaki H; Aotsuka N; Yokota A; Kanda Y; Sakura T; Nanya Y; Saitoh T; Kanamori H; Takahashi S; Okamoto S
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1553-9. PubMed ID: 25034961
[TBL] [Abstract][Full Text] [Related]
12. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Dreger P; Brand R; Hansz J; Milligan D; Corradini P; Finke J; Deliliers GL; Martino R; Russell N; Van Biezen A; Michallet M; Niederwieser D;
Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695
[TBL] [Abstract][Full Text] [Related]
13. Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
Chavez JC; Kharfan-Dabaja MA; Kim J; Yue B; Dalia S; Pinilla-Ibarz J; Anasetti C; Locke FL
Leuk Res; 2014 Oct; 38(10):1165-72. PubMed ID: 24889511
[TBL] [Abstract][Full Text] [Related]
14. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation.
Barba P; Martino R; Pérez-Simón JA; Fernández-Avilés F; Castillo N; Piñana JL; López-Anglada L; Rovira M; Bosch F; Carreras E; Corral LL; Sierra J; Valcárcel D
Biol Blood Marrow Transplant; 2014 Jan; 20(1):66-72. PubMed ID: 24141006
[TBL] [Abstract][Full Text] [Related]
15. Stem-cell transplantation for chronic lymphocytic leukemia: the 1999 perspective.
Dreger P; Michallet M; Schmitz N
Ann Oncol; 2000; 11 Suppl 1():49-53. PubMed ID: 10707779
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report.
Kim HT; Ahn KW; Hu ZH; Davids MS; Volpe VO; Antin JH; Sorror ML; Shadman M; Press O; Pidala J; Hogan W; Negrin R; Devine S; Uberti J; Agura E; Nash R; Mehta J; McGuirk J; Forman S; Langston A; Giralt SA; Perales MA; Battiwalla M; Hale GA; Gale RP; Marks DI; Hamadani M; Ganguly S; Bacher U; Lazarus H; Reshef R; Hildebrandt GC; Inamoto Y; Cahn JY; Solh M; Kharfan-Dabaja MA; Ghosh N; Saad A; Aljurf M; Schouten HC; Hill BT; Pawarode A; Kindwall-Keller T; Saba N; Copelan EA; Nathan S; Beitinjaneh A; Savani BN; Cerny J; Grunwald MR; Yared J; Wirk BM; Nishihori T; Chhabra S; Olsson RF; Bashey A; Gergis U; Popat U; Sobecks R; Alyea E; Saber W; Brown JR
Clin Cancer Res; 2019 Aug; 25(16):5143-5155. PubMed ID: 31253630
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
18. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis.
Dreger P; Brand R; Milligan D; Corradini P; Finke J; Lambertenghi Deliliers G; Martino R; Russell N; van Biezen A; Michallet M; Niederwieser D;
Leukemia; 2005 Jun; 19(6):1029-33. PubMed ID: 15830011
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia.
Kim HT; Shaughnessy CJ; Rai SC; Reynolds C; Ho VT; Cutler C; Koreth J; Gooptu M; Romee R; Nikiforow S; Armand P; Alyea EP; Antin JH; Wu CJ; Soiffer RJ; Ritz J; Brown JR
Blood Adv; 2020 Sep; 4(17):4113-4123. PubMed ID: 32882002
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas.
Heinzelmann F; Bethge W; Beelen DW; Engelhard M; Kröger N; Dreger P; Niederwieser D; Finke J; Bunjes D; Tischer J; Kobbe G; Holler E; Bornhäuser M; Stelljes M; Baurmann H; Müller A; Haubitz I; Schrezenmeier H; Müller C; Ottinger H
Bone Marrow Transplant; 2016 May; 51(5):654-62. PubMed ID: 26855152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
